Why the study?
Does sulfinpyrazone reduce cardiac mortality and sudden death in patients shortly after a documented myocardial infarction?
Does sulfinpyrazone reduce cardiac mortality and sudden death in patients shortly after a documented myocardial infarction?
Sulfinpyrazone significantly reduces sudden cardiac death during the high-risk period of 2 to 7 months following an acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Supports sulfinpyrazone shortly after MI to lower sudden death; extends RCT evidence for antiplatelet benefit in the high-risk window.
We report the results of a randomized double-blind, multicenter trial comparing sulfinpyrazone (200 mg four times a day) and a placebo in the prevention of cardiac mortality among 1558 patients followed for an average of 16 months, beginning 25 to 35 days after a documented myocardial infarction. All but one of the 106 deaths in the group were cardiac; 59 were sudden. The reduction in cardiac mortality at 24 months in the sulfinpyrazone group was 32 per cent (P = 0.058), and the reduction in sudden death was 43 per cent (P = 0.041). The benefit of sulfinpyrazone was attributable entirely to a reduction in sudden death during the second through seventh months after infarction, when there were 35 cardiac deaths in the placebo group and 17 in the sulfinpyrazone group (P = 0.021); of these deaths, 24 in the placebo group and six in the sulfinpyrazone group were sudden cardiac deaths -- a sulfinpyrazone-induced 74 per cent reduction in the calculated mortality rate (P = 0.003). We conclude that sulfinpyrazone prevents sudden cardiac death during the high-risk period shortly after an acute myocardial infarction, but that there is no further apparent effect beyond the seventh month after infarction.
No takes yet. Share an insight, caveat, or question.
A 1980 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: